"The team at Saint Luke's Cancer Institute provides early detection, expert diagnosis, personalized treatment options, and survivorship support to every patient. It's what Saint Luke's calls precision medicine: the right treatment for the right patient at the right time. We offer the region's only precision oncology program for advanced cancers that's staffed by clinical oncologists with expertise in genomic sequencing and computational biology. With our clinical trial agreement with the internationally recognized Washington University School of Medicine, we can offer more than 200 National Cancer Institute-sponsored clinical trials and industry-led studies to Saint Luke's Cancer Institute patients."

During the past decade, Saint Luke's Cancer Institute at Saint Luke's Hospital conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 56 clinical trials were completed, i.e. on average, 233.3% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 20 clinical trials were completed. i.e. 181.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Saint Luke's Cancer Institute at Saint Luke's Hospital" #1 sponsor was "SWOG Cancer Research Network" with 22 trials, followed by "Alliance for Clinical Trials in Oncology" with 19 trials sponsored, "National Cancer Institute (NCI)" with 11 trials sponsored, "Radiation Therapy Oncology Group" with 7 trials sponsored and "NSABP Foundation Inc" with 7 trials sponsored. Other sponsors include 39 different institutions and companies that sponsored additional 37 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Saint Luke's Cancer Institute at Saint Luke's Hospital" #1 collaborator was "National Cancer Institute (NCI)" with 62 trials as a collaborator, "NRG Oncology" with 7 trials as a collaborator, "Eastern Cooperative Oncology Group" with 5 trials as a collaborator, "Cancer and Leukemia Group B" with 4 trials as a collaborator and "Merck Sharp & Dohme LLC" with 4 trials as a collaborator. Other collaborators include 24 different institutions and companies that were collaborators in the rest 27 trials.

According to Clinical.Site data, the most researched conditions in "Saint Luke's Cancer Institute at Saint Luke's Hospital" are "Breast Cancer" (20 trials), "Leukemia" (9 trials), "Lung Cancer" (9 trials), "Colorectal Cancer" (8 trials) and "Lymphoma" (8 trials). Many other conditions were trialed in "Saint Luke's Cancer Institute at Saint Luke's Hospital" in a lesser frequency.

Most popular intervention types in "Saint Luke's Cancer Institute at Saint Luke's Hospital" are "Drug" (80 trials), "Other" (32 trials), "Biological" (25 trials), "Radiation" (14 trials) and "Procedure" (10 trials). Other intervention types were less common.

The name of intervention was led by "cyclophosphamide" (10 trials), "Placebo" (8 trials), "placebo" (8 trials), "Carboplatin" (7 trials) and "Paclitaxel" (7 trials). Other intervention names were less common.

The vast majority of trials in "Saint Luke's Cancer Institute at Saint Luke's Hospital" are 87 trials for "All" genders, 19 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Saint Luke's Cancer Institute at Saint Luke's Hospital". undefined are not yet recruiting, 8 are recruiting, 22 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 67 completed trials in Saint Luke's Cancer Institute at Saint Luke's Hospital, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Saint Luke's Cancer Institute at Saint Luke's Hospital, 8 "Phase 1" clinical trials were conducted, 38 "Phase 2" clinical trials and 47 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".